-
1 Comment
Malaysian Genomics Resource Centre Bhd is currently in a long term uptrend where the price is trading 47.6% above its 200 day moving average.
From a valuation standpoint, the stock is 2112.0% more expensive than other stocks from the Other sector with a price to sales ratio of 142.1.
Malaysian Genomics Resource Centre Bhd's total revenue sank by 97.3% to $136K since the same quarter in the previous year.
Its net income has dropped by 106.4% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 51.0% to $-3M since the same quarter in the previous year.
Based on the above factors, Malaysian Genomics Resource Centre Bhd gets an overall score of 2/5.
| ISIN | MYQ0155OO000 |
|---|---|
| Exchange | KLSE |
| CurrencyCode | MYR |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | 22M |
|---|---|
| Target Price | 0.8 |
| PE Ratio | None |
| Beta | 0.94 |
| Dividend Yield | None |
Malaysian Genomics Resource Centre Berhad, an investment holding company, provides genetics, genomics, immunotherapy, and biopharmaceutical services worldwide. It offers genome sequencing of various human, animal, plant, and microbes and other living organisms, such as whole genome and transcriptome sequencing, and metagenomics and metatranscriptomics services. The company also provides genome analysis services comprising bioinformatics services, including reads quality analysis, whole genome assembly, variation analysis of genomes, gene annotation, and exome and transcriptome analysis, as well as other analytical pipelines for processing ChIP-Seq data, annotating and analyzing microRNAs, and analyzing mutations; trait analysis services to screen multiple samples of previously identified genetic markers within plant and animal genomes; and trio sequencing services that provide a detailed view of an individual's DNA. In addition, it offers genetic screening services, such as Dtect, a range of test panels designed to screen for genetic markers in an individual's DNA; and cancer immunotherapy services for various types of cancer. Further, the company engages in the business relating to life sciences/cell laboratory and byproducts; distribution of beauty products and precision medicine; research, development, and commercialisation of biopharmaceutical products and services; supply of healthcare products and services; and provision of other human health services and general medical services. Additionally, it deals in capital market and derivative instruments, as well as acts as general merchants. It has a research collaboration with Universiti Sains Malaysia for exploring the genetics of Penang Woman and determining the age of the ancient Penang Women Skeleton using the Accelerator Mass Spectrometry ("AMS") dating technique. Malaysian Genomics Resource Centre Berhad was incorporated in 2004 and is headquartered in Petaling Jaya, Malaysia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 0155.KLSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
